Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Health Economics

Sign Up for Subject Area Alerts

  • Why so many significant Phase 3 results in clinical trials?
    Jerome Adda, Christian Decker, Marco Ottaviani
    medRxiv 19001495; doi: https://doi.org/10.1101/19001495
Subject Areas
All Articles
  • Addiction Medicine
  • Allergy and Immunology
  • Anesthesia (2)
  • Cardiovascular Medicine (7)
  • Dentistry and Oral Medicine
  • Dermatology (1)
  • Emergency Medicine (1)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (2)
  • Epidemiology (23)
  • Forensic Medicine
  • Gastroenterology (5)
  • Genetic and Genomic Medicine (5)
  • Geriatric Medicine
  • Health Economics (1)
  • Health Informatics (3)
  • Health Policy (2)
  • Health Systems and Quality Improvement (3)
  • Hematology
  • HIV/AIDS (2)
  • Infectious Diseases (except HIV/AIDS) (11)
  • Intensive Care and Critical Care Medicine (2)
  • Medical Education
  • Medical Ethics (1)
  • Nephrology (2)
  • Neurology (6)
  • Nursing
  • Nutrition (7)
  • Obstetrics and Gynecology (1)
  • Occupational and Environmental Health
  • Oncology (4)
  • Ophthalmology (3)
  • Orthopedics
  • Otolaryngology (2)
  • Pain Medicine (1)
  • Palliative Medicine
  • Pathology (1)
  • Pediatrics (1)
  • Pharmacology and Therapeutics
  • Primary Care Research
  • Psychiatry and Clinical Psychology (11)
  • Public and Global Health (4)
  • Radiology and Imaging (3)
  • Rehabilitation Medicine and Physical Therapy (1)
  • Respiratory Medicine (1)
  • Rheumatology (2)
  • Sexual and Reproductive Health (1)
  • Sports Medicine (4)
  • Surgery (1)
  • Toxicology
  • Transplantation (1)
  • Urology